98%
921
2 minutes
20
Colorectal cancer (CRC) is the third most common cancer worldwide. The incidence and mortality rates of CRC are significantly higher in Taiwan than in other developed countries. Genes involved in CRC tumorigenesis differ depending on whether the tumor occurs on the left or right side of the colon, and genomic analysis is a keystone in the study and treatment of CRC subtypes. However, few studies have focused on the genetic landscape of Taiwanese patients with CRC. This study comprehensively analyzed the genomes of 141 Taiwanese patients with CRC through whole-exome sequencing. Significant genomic differences related to the site of CRC development were observed. Blood metabolomic profiling and polygenic risk score analysis were performed to identify potential biomarkers for the early identification and prevention of CRC in the Taiwanese population. Our findings provide vital clues for establishing population-specific treatments and health policies for CRC prevention in Taiwan.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834628 | PMC |
http://dx.doi.org/10.3390/cells11030527 | DOI Listing |
PLoS One
September 2025
Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: Our study represents the first effort in the Eastern Mediterranean Region to identify disparities in the quality of colorectal cancer (CRC) care in Iran.
Methods: We established a collaborative registry program for non-metastatic CRC patients to evaluate survival rates between teaching cancer centers (TCCs) and a high-volume, non-teaching, non-cancer center (NTNC). The study included a diverse patient population and considered various factors such as cancer stage, margin involvement, adherence to guidelines for adjuvant and neoadjuvant treatments, emergency surgeries, socioeconomic status, and risk of surgery.
Cancer Res
September 2025
Morgridge Institute for Research, Madison, Wisconsin, United States.
Patient-derived cancer organoids (PDCOs) are a valuable model to recapitulate human disease in culture with important implications for drug development. However, current methods for rapidly and reproducibly assessing PDCOs are limited. Label-free imaging methods are a promising tool to measure organoid level heterogeneity and rapidly screen drug response in PDCOs.
View Article and Find Full Text PDFCancer Epidemiol Biomarkers Prev
September 2025
Brigham and Women's Hospital, Boston, MA, United States.
Background: Colorectal cancer (CRC) risk models routinely adjust for endoscopic screening because of a) possible confounding with other risk factors and b) possible alteration of natural history of the disease due to adenoma detection and removal.
Methods: In this study, we defined a subject as screen-covered (SC) if a colonoscopy was performed in the past 10 years, and not screen-covered (NSC) otherwise. We created CRC risk models separately for SC and NSC subjects (HRSC, HRNSC) and then obtained a screening-coverage adjusted HR estimate (HRfull) based on a weighted average of ln(HRSC) and ln(HRNSC) with weight equal to the proportion of SC person-time in the NHS population.
Cancer Res Commun
September 2025
Fred Hutchinson Cancer Center, Seattle, WA, United States.
Metastatic and relapsed osteosarcoma (OS) remains difficult to treat despite advanced surgical techniques, intensified chemotherapy, and targeted therapies. Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cells, are in their nascent stage, but remain a viable therapeutic strategy for patients with aggressive solid tumors such as OS. Folate receptor- (FOLR1) has been functionally implicated in OS pathophysiology, providing rationale as a potential therapeutic target.
View Article and Find Full Text PDFRep Pract Oncol Radiother
August 2025
Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, Poznan, Poland.
Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer.
View Article and Find Full Text PDF